EUVIMEDObjevte EUVIMED
LeserbriefOpen access · CC BY-NC-ND 4.0

Letter from Hong Kong: Vaccination trends for respiratory viral infections in Hong Kong

Ken Ka Pang Chan iD, David Shu Cheong Hui iD

Respirology · 2024-11 · 29 (11) · 998-1000

DOI: 10.1111/resp.14824 ↗

At a glance

Leserbrief in Respirology, published online on 2024-08-27. Written by Ken Ka Pang Chan and 1 co-authors. Institution: Department of Medicine & Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong. Cited 1 times so far (Crossref); 5 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The epidemiology of respiratory viral infections and vaccination uptake in Hong Kong has changed since the emergence of SARS-CoV-2. We would like to share our insights on the acceptance of COVID-19 and influenza vaccines, as well as the challenges posed by other respiratory infections. Hong Kong was one of the first regions to tackle the COVID-19 pandemic several years ago. As COVID-19 turns into an endemic disease, the Hong Kong Special Administrative Region (HKSAR) government has introduced a 'living with COVID-19' policy. Although mandatory non-pharmaceutical interventions (NPI), such as mask-wearing and social distancing, have been lifted, the government emphasizes continued vigilance against COVID-19 and other respiratory viruses. Following the relaxation of NPI in late 2022, a significant decline in the uptake of COVID-19 booster vaccines has occurred. While there were high uptake rates for the initial doses (93% and 80% for the second and third doses, respectively), only a small percentage of the population (less than 5%) has received fifth or sixth booster doses.1 This decline may be attributed to 'vaccination fatigue' resulting from frequent and mandatory COVID-19 vaccinations during the pandemic. Additionally, the perceived lower disease severity of the latest Omicron variants has contributed to reduced booster uptake. Vaccination remains the most effective strategy to prevent COVID-19. Given the rapidly evolving variants of interest (VOI) and variants under monitoring (VUM), the World Health Organization (WHO) recommends using a monovalent JN.1 lineage as the antigen in the next COVID-19 vaccine formulation. This choice is likely to produce higher neutralizing antibodies against co-circulating JN.1 variants (e.g., KP.2) compared to an XBB.1.5 or related vaccine antigen. The HKSAR government will follow this recommendation and procure the monovalent JN.1-lineage vaccines.2 The HKSAR government has been providing COVID-19 vaccines for free to high-risk groups. The accessibility of vaccination across geographical locations should facilitate public uptake (Figure 1). However, the current low vaccination rate and the foreseeable further decline remain concerning. Educating the general public about the need for regular (i.e., every 6–12 months) vaccinations in high-risk groups and addressing misconceptions about vaccine safety are crucial in our long-term battle against the COVID-19 pandemic. Contrary to the COVID-19 vaccines, the general public has shown better acceptance towards influenza vaccines. There has been a progressive increase in the uptake rate of influenza vaccination in Hong Kong. During the COVID-19 pandemic, the circulation of other respiratory viral infections was heavily suppressed by tight infection control and social distancing measures. Following the relaxation of NPIs, there has been a rebound of these infections, including influenza. The seasonality of influenza activity has also been disrupted after the COVID-19 pandemic. Since the initial surge in April 2023, the influenza season has become protracted but with a smaller amplitude than before the pandemic. The HKSAR government has continued the Government Vaccination Programme and Vaccination Subsidy Scheme to provide free and subsidized influenza vaccinations, encouraging uptake and offering enhanced protection for elderly people and high-risk groups. Notably, there has been a progressive increase in the uptake rate for the general population and elderly people over the past 3 years compared to pre-COVID-19 times. The latest vaccination rates are 48.6% for ages 6 months to 6 years, 68.0% for ages 6–12 years, and 51.4% for those aged 65 years or above.3 This rise is encouraging, but more effort is needed to reach the international target of a 75% influenza vaccine uptake rate. Despite the higher vaccine uptake rate, the incidence of severe influenza infection and associated mortality is higher than before the COVID-19 era due to a lack of exposure to influenza and related immunity from 2020 to 2023. Among patients with laboratory-confirmed influenza admitted to public hospitals (from 7 January 2014 to 17 July 2024), the in-hospital mortality rate was 3.9%, higher than the historical range of 1.9% (2015/16 winter season) to 3.3% (2015 summer season).4 Only a very low level of reduced oseltamivir susceptibility among tested influenza A (all were influenza A subtype H1 viruses) viruses were identified, which is unlikely to contribute to the higher mortality rate. Similar to influenza, respiratory syncytial virus (RSV) infections have resurged since last year. The clinical burden of RSV has gained attention recently due to the introduction of the RSV vaccines in the commercial market. However, as of the time of writing, the government has not procured the RSV vaccines in the public vaccination scheme. Several factors may hinder the adoption of RSV vaccination in the general population, including the lack of updated local data on the epidemiology and clinical burden of RSV infection, inadequate public education on RSV, and vaccination fatigue after the COVID-19 pandemic. It would be desirable for the government to monitor the vaccination uptake rate if the RSV vaccine is introduced for free to the public, or at least for the high-risk individuals. Following the COVID-19 pandemic, Hong Kong returned to normalcy last year. We are pleased to host the 28th Congress of APSR this year. The congress will be a great platform for exchanging knowledge and insights on public health measures and the latest advances in managing respiratory infections. We welcome your attendance and look forward to meeting you in Hong Kong. David Shu Cheong Hui and Ken Ka Pang Chan are Editorial Board members of Respirology and were excluded from all editorial decision-making related to the acceptance of this article for publication.

Subjects

Author keywords

COVID‐19influenzarespiratory syncytial virusvaccination fatiguevaccine

Authors and institutions

  • Department of Medicine & Therapeutics, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong.
  • Li Ka Shing Institute of Health Sciences, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, Hong Kong.

ORCID profiles: Ken Ka Pang Chan, David Shu Cheong Hui

Cite

APA

Chan, K. K. P., & Hui, D. S. C. (2024). Letter from Hong Kong: Vaccination trends for respiratory viral infections in Hong Kong. Respirology, 29(11), 998-1000. https://doi.org/10.1111/resp.14824

Vancouver

Chan KKP, Hui DSC. Letter from Hong Kong: Vaccination trends for respiratory viral infections in Hong Kong. Respirology. 2024;29(11):998-1000. doi:10.1111/resp.14824

BibTeX
@article{Chan2024,
  author = {Chan, Ken Ka Pang and Hui, David Shu Cheong},
  title = {Letter from Hong Kong: Vaccination trends for respiratory viral infections in Hong Kong},
  journal = {Respirology},
  year = {2024},
  volume = {29},
  number = {11},
  pages = {998--1000},
  doi = {10.1111/resp.14824}
}
Start for free →